Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coligermina
- Development stage
- Unknown
- Lead developer
- Bruschettini
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Coligermina is a gastrofunctional oral suspension developed by Bruschettini for the treatment of infant colic, meteorism, aerophagia, and dyspeptic disorders in infants, children, and adults. It is a fixed-dose combination of simethicone and spores of the probiotic bacterium *Bacillus coagulans* (historically referred to as *Lactobacillus sporogenes*). Simethicone acts locally in the gastrointestinal tract as a surfactant, reducing the surface tension of gas bubbles to facilitate their coalescence and elimination. Concurrently, *Bacillus coagulans* spores survive gastric acidity to germinate in the intestines, where they produce lactic acid and help restore a balanced gut microbiota. Coligermina is approved and marketed in Italy and other regions as a CE Class IIa medical device.
- Brand names
- Coligermina
- Other names
- simethicone + Bacillus coagulanssimethicone + Lactobacillus sporogenes
Beyond the preview
Go deeper on Coligermina.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Coligermina.